Aryeh Abeles, MD
Rheumatology · Meriden, CTNPI 1285737155
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Johnson & Johnson at 37.0% of the total. Among rheumatology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 853 payments — averaging $47.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$15K
- AbbVie$10K
- E.r. Squibb & Sons, L.L.C.$4K
- Janssen Scientific Affairs, LLC$3K
- UCB, Inc.$2K
- Amgen$2K
- plus $5K from 22 others
What the payments were for
- Consulting fees$22,01654%
- Travel & lodging$5,64514%
- Food & beverage$12,92232%
- Education$2191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 85 | $15,114 |
| AbbVie | 176 | $9,918 |
| E.r. Squibb & Sons, L.L.C. | 59 | $4,480 |
| Janssen Scientific Affairs, LLC | 1 | $2,750 |
| UCB, Inc. | 126 | $1,882 |
| Amgen(2 entities) | 131 | $1,625 |
| Lilly USA, LLC | 48 | $871 |
| Radius Health, Inc. | 35 | $706 |
| AstraZeneca(2 entities) | 33 | $628 |
| GSK | 29 | $552 |
| Aurinia Pharma U.S., Inc. | 23 | $418 |
| Sanofi | 19 | $332 |
| Sobi, Inc | 18 | $301 |
| Pfizer | 20 | $289 |
| Genentech USA, Inc. | 17 | $288 |
| Boehringer Ingelheim | 8 | $157 |
| Fresenius Kabi USA, LLC | 4 | $96 |
| Novartis | 4 | $83 |
| Organon | 5 | $79 |
| Hikma Pharmaceuticals USA | 3 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $37 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $21 |
| Gilead | 1 | $21 |
| Octapharma USA, Inc. | 1 | $21 |
| Sandoz | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$16,938
- SIMPONI ARIA$9,688
- Rinvoq$6,969
How this compares
$40,801 in reported general payments places this provider in the 90th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 69 | $537,701 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 39 | $290,778 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $231,909 |
| EnbrelEtanercept | 29 | $209,153 |
| TavneosAvacopan | 12 | $190,675 |
| Humira(Cf) PenAdalimumab | 21 | $141,200 |
| OtezlaApremilast | 21 | $98,741 |
| OlumiantBaricitinib | 24 | $75,484 |
| Xeljanz XrTofacitinib Citrate | 12 | $69,239 |
| SaphneloAnifrolumab-Fnia | 13 | $68,405 |
| XeljanzTofacitinib Citrate | 12 | $68,293 |
| KevzaraSarilumab | 15 | $64,941 |
| Actemra ActpenTocilizumab | 11 | $40,739 |
| ActemraTocilizumab | 11 | $13,240 |
| Mycophenolate Mofetil | 24 | $7,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Tavneos, Otezla | $1,625 | $498,56962 claims |
| PfizerOctagam, Xeljanz | $289 | $359,07151 claims |
| Lilly USA, LLCOlumiant | $871 | $75,48424 claims |
| AstraZenecaSaphnelo | $628 | $68,40513 claims |
| SanofiKevzara | $332 | $64,94115 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $35 | $2,62435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 rheumatology providers in Connecticut.
Other rheumatology in Meriden
- Micha AbelesMeriden$19K
- Kenneth MillerDanbury$873K
- Robert SchoenGuilford$638K
- Bret SohnStamford$447K
- Fotios KoumpourasNorth Haven$314K
- James SeiboldFarmington$300K
- Michael SpiegelDanbury$215K
- John MagaldiTorrington$157K
- Archana SharmaBristol$98K
- Richard RoseffDanbury$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.